Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib

Haruko Shima; Nobutaka Kiyokawa; Masashi Miharu; Akihiko Tanizawa; Hidemitsu Kurosawa; Akihiro Watanabe; Masaki Ito; Chikako Tono; Yuki Yuza; Hideki Muramatsu; Noriko Hotta; Masahiko Okada; Kazuko Hamamoto; Ryosuke Kajiwara; Akiko M Saito; Keizo Horibe; Shuki Mizutani; Souichi Adachi; Eiichi Ishii; Hiroyuki Shimada

doi:10.1002/pbc.26478

Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26478. Epub 2017 Feb 24.

Authors

Haruko Shima^{1

2}, Nobutaka Kiyokawa³, Masashi Miharu³, Akihiko Tanizawa⁴, Hidemitsu Kurosawa⁵, Akihiro Watanabe⁶, Masaki Ito⁷, Chikako Tono⁸, Yuki Yuza⁹, Hideki Muramatsu¹⁰, Noriko Hotta¹¹, Masahiko Okada¹², Kazuko Hamamoto¹³, Ryosuke Kajiwara¹⁴, Akiko M Saito², Keizo Horibe², Shuki Mizutani¹⁵, Souichi Adachi¹⁶, Eiichi Ishii¹⁷, Hiroyuki Shimada¹

Affiliations

¹ Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
² Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan.
³ Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
⁴ Department of Pediatrics, University of Fukui Faculty of Medical Sciences, Fukui, Japan.
⁵ Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.
⁶ Department of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan.
⁷ Department of Pediatrics, Soma General Hospital, Fukushima, Japan.
⁸ Department of Pediatrics, Iwate Prefectural Chubu Hospital, Aomori, Japan.
⁹ Department of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
¹⁰ Department of Pediatrics, Nagoya University Graduate School of Medicine, Aichi, Japan.
¹¹ Department of Pediatrics, Japan Community Healthcare Organization Tokuyama Central Hospital, Yamaguchi, Japan.
¹² Department of Pediatrics, Nagasaki University School of Medicine, Nagasaki, Japan.
¹³ Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
¹⁴ Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa, Japan.
¹⁵ Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
¹⁶ Human Health Sciences, Kyoto University, Kyoto, Japan.
¹⁷ Department of Pediatrics, Ehime University Graduate School of Medicine, Ehime, Japan.

PMID: 28233439
DOI: 10.1002/pbc.26478

Abstract

Bone marrow samples of newly diagnosed children with chronic-phase chronic myeloid leukemia (CML) were obtained at diagnosis and after imatinib initiation and stained with anti-human CD34, CD38, CD123, CD45RA, cMpl, and lineage antibodies. Flow cytometric analysis revealed that granulocyte macrophage progenitor predominance in CML progenitors at diagnosis and elevated cMpl expression in bone marrow progenitors at 3 months may predict poor outcome in children with chronic-phase CML treated with imatinib. We recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and guide CML management.

Keywords: cMpl; chronic myeloid leukemia; flow cytometry.

MeSH terms

Adolescent
Antineoplastic Agents / therapeutic use*
Bone Marrow Cells / pathology
Child
Child, Preschool
Female
Flow Cytometry / methods*
Humans
Imatinib Mesylate / therapeutic use*
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Male
Neoplastic Stem Cells / pathology
Treatment Outcome

Substances

Antineoplastic Agents
Imatinib Mesylate